Rafael Holdings annual gross margin
2021
2022
2023
2024
Rafael Holdings Gross Margin Growth & History (RFL)
Rafael Holdings's gross margin was 75.82% for fiscal 2024.
View full Rafael Holdings company overviewRafael Holdings annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-07-31 | 75.82% | −24.18 pp |
| 2023 | 2023-07-31 | 100.00% | +853.41 pp |
| 2022 | 2022-07-31 | −753.41% | −458.28 pp |
| 2021 | 2021-07-31 | −295.14% | — |
Rafael Holdings quarterly gross margin
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-04-30 | 95.53% | +6.58 pp |
| Q2 2026 | 2026-01-31 | 94.31% | +43.66 pp |
| Q1 2026 | 2025-10-31 | 96.25% | +25.16 pp |
| Q3 2025 | 2025-04-30 | 88.95% | +14.25 pp |
| Q2 2025 | 2025-01-31 | 50.65% | — |
| Q1 2025 | 2024-10-31 | 71.09% | — |
| Q3 2024 | 2024-04-30 | 74.70% | −25.30 pp |
| Q3 2023 | 2023-04-30 | 100.00% | +1051.32 pp |
| Q2 2023 | 2023-01-31 | 100.00% | +1400.00 pp |
| Q1 2023 | 2022-10-31 | −255.71% | +81.46 pp |
| Q4 2022 | 2022-07-31 | −1,101.45% | — |
| Q3 2022 | 2022-04-30 | −951.32% | — |
| Q2 2022 | 2022-01-31 | −1,300.00% | — |
| Q1 2022 | 2021-10-31 | −337.17% | — |
Rafael Holdings gross margin trends
Between the periods ended 2021-07-31 and 2024-07-31, Rafael Holdings's gross margin increased from −295.14% to 75.82%, a change of +370.96 percentage points. The latest reported quarter, Q3 2026, shows 95.53%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rafael Holdings source filings ↗Community posts
Rafael submits remibetadex for FDA review despite a missed pivotal endpoint
Rafael Holdings ($RFL) said its Cyclo Therapeutics subsidiary submitted a US marketing application for remibetadex, also called Trappsol Cyclo, for neurological and internal-organ manifestations of Niemann-Pick disease type C. The proposed ...
